From Biology to Therapy: The CLL Success Story

From Biology to Therapy: The CLL Success Story

Abstract. Chemoimmunotherapy has been the standard of care for patients with chronic lymphocytic leukemia (CLL) over the last decade. Advances in monoclonal antibody technology have resulted in the development of newer generations of anti-CD20 antibodies with improved therapeutic effectiveness. In p...

Full description

Bibliographic Details
Main Authors:	Deyan Y. Yosifov, Christine Wolf, Stephan Stilgenbauer, Daniel Mertens
Format:	Article
Language:	English
Published:	Wolters Kluwer 2019-04-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000175

Similar Items

Current Treatment Options in CLL
by: Moritz Bewarder, et al.
Published: (2021-05-01)

Critical molecular pathways in CLL therapy
by: Gerardo Ferrer, et al.
Published: (2018-03-01)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
by: Hui Zhang, et al.
Published: (2020-05-01)

Therapy of chronic lymphocytic leukemia (CLL) - from past to present
by: Anna Gumieniczek, et al.
Published: (2020-02-01)

Targeting CLL-1 for acute myeloid leukemia therapy
by: Hongbing Ma, et al.
Published: (2019-04-01)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
by: Lily Mahapatra, et al.
Published: (2021-03-01)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
by: Natalia Timofeeva, et al.
Published: (2021-04-01)

Three years of ibrutinib in CLL
by: Forconi, Francesco
Published: (2015)

Analysis of the tumour microenvironment in CLL
by: Hamilton, Emma
Published: (2013)

Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL
by: Justyna A. Wierzbinska, et al.
Published: (2020-03-01)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020-08-01)

Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL
by: Gonzalo Blanco, et al.
Published: (2018-06-01)

Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
by: William K Decker, et al.
Published: (2012-01-01)

FAVORABLE OUTCOME IN CLL PATIENTS NOT TREATED DESPITE PRESENTING IWCLL CRITERIA: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN CLL GROUP
by: F.M. Marques, et al.
Published: (2020-11-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

Targeting Bruton’s Tyrosine Kinase in CLL
by: Inhye E. Ahn, et al.
Published: (2021-06-01)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
by: Yucai Wang, et al.
Published: (2021-08-01)

Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target
by: Carlos Cuesta-Mateos, et al.
Published: (2021-03-01)

Advocating the need of a systems biology approach for personalised prognosis and treatment of B-CLL patients
by: Hemanth Tummala, et al.
Published: (2012-12-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

Perturbation of the normal immune system in patients with CLL
by: Forconi, Francesco, et al.
Published: (2015)

Mutations driving CLL and their evolution in progression and relapse
by: Lander, Eric Steven
Published: (2017)

The study of endocrine hormone changes in patients with CLL
by: Vojgani M, et al.
Published: (1993-04-01)

Proteomics and Drug Repurposing in CLL towards Precision Medicine
by: Dimitra Mavridou, et al.
Published: (2021-07-01)

Celebrating 20 Years of IGHV Mutation Analysis in CLL
by: Nicholas Chiorazzi, et al.
Published: (2020-02-01)

The regulatory capacity of B cells directs the aggressiveness of CLL
by: Audrey Mohr, et al.
Published: (2019-03-01)

Experiences in the design and implementation of phase II trials in CLL
by: Cohen Dena R, et al.
Published: (2011-12-01)

Impact of Computer Remote Education on CLL Learning and Solutions
by: Xuezhou Liu
Published: (2018-03-01)

Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)
by: Andrea Sitlinger, et al.
Published: (2021-05-01)

B-cell chronic lymphocyte leukemia (B-CLL)
by: P. Kokhaee
Published: (2007-11-01)

Rapid analysis and design of CLL resonant power converters
by: Gould, Christopher R.
Published: (2006)

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
by: Alexander Egle, et al.
Published: (2019-04-01)

Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets
by: Irene López-Oreja, et al.
Published: (2021-06-01)

Non-Coding RNAs: The “Dark Side Matter” of the CLL Universe
by: Marcello Francesco Lingua, et al.
Published: (2021-02-01)

A Multi-Reconfigurable CLL-Loaded Planar Monopole Antenna
by: M. M. Fakharian, et al.
Published: (2020-06-01)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

Application Of Raman Microscopy For The Diagnosis Of The Chronic Lymphocytic Leukemia (Cll)
by: M. Fere, et al.
Published: (2016-06-01)

The ultrastructural investigation of mitochondria in B-CLL cells during apoptosis
by: Braju��ković Goran R., et al.
Published: (2004-01-01)

Aberrant promoter hypomethylation in CLL: does it matter for disease development?
by: Garland Michael Upchurch, et al.
Published: (2016-08-01)

Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation.
by: Patricia Freund, et al.
Published: (2016-01-01)